|1.||Morel, Yannis: 3 articles (01/2012 - 01/2010)|
|2.||Paturel, Carine: 2 articles (01/2012 - 01/2010)|
|3.||Conforti, Rosa: 2 articles (03/2011 - 01/2010)|
|4.||Zitvogel, Laurence: 2 articles (03/2011 - 01/2010)|
|5.||Heinz, A: 1 article (03/2014)|
|6.||Wolfheimer, S: 1 article (03/2014)|
|7.||Schülke, S: 1 article (03/2014)|
|8.||Maxeiner, J: 1 article (03/2014)|
|9.||Taube, C: 1 article (03/2014)|
|10.||Reuter, S: 1 article (03/2014)|
|1.||Breast Neoplasms (Breast Cancer)
08/01/1996 - "The synthetic polynucleotide polyadenylic-polyuridylic acid (polyA:polyU) has shown antitumor activity in murine studies and human breast cancer. "
02/25/1984 - "The results of a randomised trial of polyadenylic-polyuridylic acid given as adjuvant treatment for operable breast cancer were reviewed after a mean follow up period of 87 months. "
02/25/1984 - "Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial."
06/01/2013 - "Collectively, our data indicated that human breast cancer cell line (MDA-MB-231) was highly responsive to poly (A:U). "
08/01/1988 - "Polyadenylic-polyuridylic acid as adjuvant in the treatment of operable breast cancer: recent results."
10/01/1985 - "Clinical trials using polyadenylic-polyuridylic acid as an adjuvant to surgery in treating different human tumors."
04/01/1985 - "A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients."
06/01/2013 - "The antimetastatic effect of direct poly (A:U) and TLR3 interactions in MDA-MB-231 cells could provide new approaches in malignant tumor therapeutic strategy."
01/15/2010 - "We took advantage of two TLR3-expressing tumor models that produced large amounts of CCL5 (a CCR5 ligand) and CXCL10 (a CXCR3 ligand) in response to type I IFN and poly(A:U), both in vitro and in vivo. "
05/01/1985 - "Polyadenylic.polyuridylic acid in the cotreatment of cancer."
09/01/1992 - "Polyadenylic:polyuridylic acid-induced protection of BALB/c mice against acute murine cytomegalovirus infection."
07/01/1978 - "abortus and poly A : U were given a second infection 2 days later, with either Br. "
07/01/1978 - "The double stranded polynucleotide, poly A : U, when administered intraperitoneally at the same time as intravenous infection with Brucella abortus, suppressed the growth of that organism in the spleen and liver of mice. "
12/01/1978 - "Freshly perfused ground worms or a putative membrane antigen extracted with 0.5 M KC1 from adult worms, when injected together with Corynebacterium parvum (or in a single experiment with poly [A : U]), resulted in a significant reduction in worm burden of a challenge infection with S. "
07/01/1978 - "abortus or Listeria monocytogens, the second infection was exacerbated, indicating a biphasic effect of poly A : U and antigen."
03/01/1976 - "The age-dependent efficacy of polyadenylic-polyuridylic acid therapy upon the development of spontaneous leukemia in AKR mice."
03/01/1974 - "Prophylactic therapy of spontaneous leukemia in AKR mice by polyadenylic-polyuridylic acid."
11/01/1975 - "Because the opposite result was formerly observed for AKR spontaneous leukemia, the data indicate the polyadenylic-polyuridylic acid has no generalized antineoplastic effect upon spontaneous tumors genetically associated with specific murine strains."
|5.||Chronic Hepatitis (Chronic Active Hepatitis)
03/01/1994 - "Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B."
09/01/1993 - "Effect of polyadenylic.polyuridylic acid on cellular responses of peripheral blood mononuclear cells from patients with chronic active hepatitis B."
09/01/1993 - "We have investigated in vitro proliferative responses of peripheral blood mononuclear cells and productions of interferon-gamma and soluble interleukin-2 receptors by these cells from 6 patients with chronic active hepatitis B immediately before and 24 hours after a single intravenous injection of 100 mg of polyadenylic.polyuridylic acid. "
03/01/1994 - "In order to assess whether polyadenylic.polyuridylic acid [poly(A).poly(U)] can be used as a new therapeutic agent for the treatment of chronic hepatitis B, 19 patients with histologically proven chronic active hepatitis B were injected intravenously with 100-150 mg of poly(A).poly(U) weekly for six weeks. "
|2.||Poly U (U, Poly)
|8.||Coloring Agents (Dyes)
|10.||Ribosomal DNA (rDNA)
|2.||Drug Therapy (Chemotherapy)